Collegium Pharmaceutical, Inc. (COLL)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Collegium Pharmaceutical, Inc. currently loses $8.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 11 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Collegium Pharmaceutical’s adjusted EPS topped expectations while revenue came in line in the second fiscal quarter of 2026, based on preliminary results reported August 6, 2026. Revenue rose 6.3% to about $200.0 million (up from $188.0 million a year ago), with the consensus comparison showing revenue of $199.9 million in line with the $199.6 million estimate (+0.1%). On the bottom line, adjusted EPS of $1.92 topped the $1.72 estimate (+11.6%) and was up from $1.68 a year ago (+14.3%). Profitability held at a gross margin of roughly 55%, as gross profit reached about $110.3 million. The quarter also generated operating cash flow of about $71.3 million. For the next period, consensus calls for EPS of $1.86 on revenue of $218.5 million.
Next report — what to expect
Collegium Pharmaceutical, Inc. (COLL) is set to report earnings on November 5, 2026. Wall Street expects EPS of $1.78 on revenue of $218.4 million. For trailing context, revenue grew +6.3% year over year last quarter. Collegium has beaten EPS in 7 of 8 most recent quarters, so attention may center on whether it extends that pattern.
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. develops and markets prescription pain medicines in the healthcare sector, focused on specialty branded opioids and related therapies. Listed on the NASDAQ as COLL, the company generated $780.6 million of revenue in FY2025 and operates within specialty and generic drug manufacturing.
Today's Snapshot
COLL closed 2.3% below yesterday's close, in line with a weaker sector. COLL reports earnings on 5 November.
Trading Volume
Below 10d avg (690.4K)
662.3K
vs S&P 500 Today
Underperforming Market
-1.78%
Updated: October 23, 2026 at 20:19 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$22.81 - $32.87Sell
- RSI (14)49.03Neutral
- Stochastic %K (14, 3, 3)64.60Neutral
- MACD Level (12, 26)-0.18Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.